On March 9, 2022 Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, reported that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, which is being held April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana (Press release, Shattuck Labs, MAR 9, 2022, View Source [SID1234609758]). The first poster will highlight preclinical data from the company’s GADLEN platform, while the second will highlight preclinical data from SL-9258 (TIGIT-Fc-LIGHT), derived from the company’s ARC platform, demonstrating its ability to broaden the activity of checkpoint inhibitors through targeted myeloid cell and effector lymphocyte activation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Title: Bispecific gamma delta T cell engagers containing butyrophilin 2A1/3A1 heterodimeric fusion protein efficiently activate Vg9Vd2 T cells and promote tumor cell killing
Presenter: Dr. Anne Lai, Ph.D., Principal Scientist, Shattuck
Session: Immunology – Immunomodulatory Agents and Interventions 2
Date/Time: Tuesday, April 12, 2022, 1:30 p.m. to 5:00 p.m. ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Abstract Number: 3514
Title: LIGHT (TNFSF14) costimulation with TIGIT blockade broadens the activity of checkpoint inhibitors (CPIs) into CPI refractory and resistant tumors through targeted myeloid cell and effector lymphocyte activation
Presenters: Dr. George Fromm, Ph.D., Vice President of Research and Development, Shattuck, and Kyung Jin Yoo, Research Associate, Shattuck
Session: Immunology – Combination Immunotherapies 2
Date/Time: Wednesday, April 13, 2022, 9:00 a.m. to 12:30 p.m. ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Abstract Number: 4214
Additional meeting information can be found on the AACR (Free AACR Whitepaper) website, View Source The posters will be available under the Events & Presentations section of the Company’s website shortly after the event.